Merck and Moderna’s Cancer Vaccine Combination Meets Phase III Endpoints in Melanoma

Company: Merck & Moderna · Event Type: Phase III Topline Data · Product: Intismeran Autogene (mRNA-4157/V940) + Pembrolizumab · Mechanism: Individualized Neoantigen Therapy + Anti-PD-1 · Indication: Resected Cutaneous Melanoma · Announcement Date: August 19, 2026 Summary Merck and Moderna reported that the randomized Phase…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding
Samsung Biologics Moves Into Peptide Manufacturing
Boulevard Bio Launches with $65 Million
GSK – $1B SiranBio Oligo Deal